降糖药物导致ANCA相关性血管炎肾损害1例报道及文献回顾

doi:10.3969/j.issn.1006-7795.2024.05.025

首都医科大学学报 ›› 2024, Vol. 45 ›› Issue (5): 912-916.doi: 10.3969/j.issn.1006-7795.2024.05.025

降糖药物导致ANCA相关性血管炎肾损害1例报道及文献回顾

朱育林^1,2,李佳夷^1,2,陈钊^1,2,陈香慧^1,2,史佳慧^1,2,杨霞^1,2,姚纲练^1,2,卢家美^1,2,付荣国^{1, 2*}

1. 西安交通大学第二附属医院肾病科，西安 710004；2. 西安交通大学第二附属医院泌尿肾脏病院，西安 710004

收稿日期:2024-08-05 出版日期:2024-10-21 发布日期:2024-10-18
通讯作者: 付荣国 E-mail:pipifu@ 126. com
基金资助:
国家自然科学基金资助项目(82170697)，陕西省自然科学基础研究计划项目一般项目（面上项目）（2022JM-4798）。

Received:2024-08-05 Online:2024-10-21 Published:2024-10-18
Supported by:
This study was supported by National Natural Science Foundation of China(82170697), General Research of Natural Science Project of Shaanxi Province（2022JM-4798）

摘要/Abstract

朱育林, 李佳夷, 陈钊, 陈香慧, 史佳慧, 杨霞, 姚纲练, 卢家美, 付荣国. 降糖药物导致ANCA相关性血管炎肾损害1例报道及文献回顾[J]. 首都医科大学学报, 2024, 45(5): 912-916.

［1］Kronbichler A, Bajema I M, Bruchfeld A, et al. Diagnosis and management of ANCA-associated vasculitis［J］. Lancet, 2024, 403(10427): 683－698.
［2］Kojima T, Oda T K H. Role of complement activation in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis［J］. Front Med, 2022, 9: 1031445.
［3］Fauci A S, Haynes B F, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years［J］. Ann Intern Med, 1983, 98(1): 76－85.
［4］Weng C H, Liu Z C. Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis［J］. Chin Med J, 2019, 132(23): 2848－2855.
［5］Yaseen K, Nevares A, Tamaki H. A spotlight on Drug-Induced vasculitis［J］. Curr Rheumatol Rep, 2022, 24(11): 323－336.
［6］Brown E, Heerspink H J L, Cuthbertson D J, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications［J］. Lancet, 2021, 398(10296): 262－276.
［7］Zhao X, Wang M H, Wen Z T, et al. GLP-1 receptor agonists: beyond their pancreatic effects［J］. Front Endocrinol, 2021, 12: 721135.
［8］Seksaria S, Dutta B J, Kaur M, et al. Role of GLP-1 receptor agonist in diabetic cardio-renal disorder: recent updates of clinical and pre-clinical evidence［J］. Curr Diabetes Rev, 2024, 20(6): e090823219597.
［9］López-Ruiz A, del Peso-Gilsanz C, Meoro-Avilés A, et al. Acute renal failure when exenatide is co-administered with diuretics and angiotensin Ⅱ blockers［J］. Pharm World Sci, 2010, 32(5): 559－561.
［10］Leehey D J, Rahman M A, Borys E, et al. Acute kidney injury associated with semaglutide［J］. Kidney Med, 2021, 3(2): 282－285.
［11］Borkum M, Lau W, Blanco P, et al. Semaglutide-Associated acute interstitial nephritis: a case report［J］. Kidney Med, 2022, 4(12): 100561.
［12］Sreih A G, Cronin K, Shaw D G, et al. Diagnostic delays in vasculitis and factors associated with time to diagnosis［J］. Orphanet J Rare Dis, 2021, 16(1): 184.
［13］Yaseen K, Nevares A, Tamaki H. A spotlight on Drug-Induced vasculitis［J］. Curr Rheumatol Rep, 2022, 24(11): 323－336.
［14］Yaseen K, Mandell B F. ANCA associated vasculitis (AAV): a review for internists［J］. Postgrad Med, 2023, 135(sup1): 3－13.
［15］Kitching A R, Anders H J, Basu N, et al. ANCA-associated vasculitis［J］. Nat Rev Dis Primers, 2020, 6(1): 71.
［16］Geetha D, Jefferson J A. ANCA-Associated vasculitis: core curriculum 2020［J］. Am J Kidney Dis, 2020, 75(1): 124－137.
［17］Nakazawa D, Masuda S, Tomaru U, et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis［J］. Nat Rev Rheumatol, 2019, 15(2): 91－101.
［18］Trivioli G, Marquez A, Martorana D, et al. Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management［J］. Nat Rev Rheumatol, 2022, 18(10): 559－574.
［19］Chalkia A, Jayne D. ANCA-associated vasculitis-treatment standard［J］. Nephrol Dial Transplant, 2024, 39(6): 944－955.
［20］Weng C H, Liu Z C. Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis［J］. Chin Med J, 2019, 132(23): 2848－2855.
［21］Shetty R, Basheer F T, Poojari P G, et al. Adverse drug reactions of GLP-1 agonists: a systematic review of case reports［J］. Diabetes Metab Syndr, 2022, 16(3): 102427.
［22］Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly Semaglutide in adolescents with obesity［J］. N Engl J Med, 2022, 387(24): 2245－2257.
［23］Chao A M, Tronieri J S, Amaro A, et al. Semaglutide for the treatment of obesity［J］. Trends Cardiovasc Med, 2023, 33(3): 159－166.
［24］Singh G, Krauthamer M, Bjalme-Evans M W. Wegovy (Semaglutide): a new weight loss drug for chronic weight management ［J］. J Investig Med, 2022, 70(1): 5－13.
［25］曾英彤, 王妍, 张宏亮. 胰高血糖素样肽-1受体激动剂（GLP-1RA）临床应用医药专家共识［J/OL］. 今日药学, 1－38［2024-07-31］. http://kns.cnki.net/kcms/detail/44.1650.R.20230421.0935.004.html.
［26］Chao A M, Tronieri J S, Amaro A, et al. Semaglutide for the treatment of obesity［J］. Trends Cardiovasc Med, 2023, 33(3): 159－166.
［27］Smits M M, Van Raalte D H. Safety of semaglutide［J］. Front Endocrinol (Lausanne), 2021, 12: 645563.
［28］Gao X Q, Hua X L, Wang X, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials［J］. Front Pharmacol, 2022, 13: 935823.
［29］Amaro A, Sugimoto D, Wharton S. Efficacy and safety of Semaglutide for weight management: evidence from the STEP program［J］. Postgrad Med, 2022, 134(sup1): 5－17.

降糖药物导致ANCA相关性血管炎肾损害1例报道及文献回顾

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价